The continued development and support of such sectors and processes will be crucial for Malaysia’s transition from an upper-middle-income to a high-income nation, which is expected to occur between 2024 and 2028.were surprised, therefore when it emerged recently the government is co-sponsoring a potential deal at the World Trade Organization in Geneva to suspend intellectual property rights for all Covid-19 technologies .
The 12th Malaysian Plan 2021–2025 recently tabled in Parliament saw the announcement of the National Vaccine Development Roadmap which aims to ensure that this country is able to develop and produce its own human vaccines as part of increasing pandemic preparedness and resilience. The need to protect intellectual property rights also featured prominently in the 12MP, with an emphasis of translating the fruits of research and development into high value-added products. This will undoubtedly include potentially hundreds of millions of ringgit in innovations and products in the life sciences.
Malaysia faces challenges related to health-related IP where its actions are currently perceived to not reflect its commitments. The use of government-use licensing of the innovative Hepatitis C drug sofosbuvir as a cost-containment measure, earned Malaysia an unhelpful “out of cycle” review from the United States government.
Unfortunately, perceptions of this country as a risky location for biopharma investment will also be heightened by the government’s decision to co-sponsor the WTO waiver on Covid-related IP.
United States United States Latest News, United States United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: malaymail - 🏆 1. / 86 Read more »